| Literature DB >> 35051935 |
Sefik Gorkem Fatihoglu1, Farzin Jam2, Sercan Okutucu3, Ali Oto3.
Abstract
OBJECTIVE: Fingertip-reactive hyperemia-peripheral artery tonometry (RH-PAT) is an emerging novel noninvasive method for evaluating endothelial function. We aimed to evaluate endothelial function with fingertip-reactive hyperemia by RH-PAT in symptomatic patients undergoing elective coronary angiography and to assess the relationship between the degree of endothelial dysfunction (ED) and the presence and the severity of coronary artery disease (CAD). SUBJECTS AND METHODS: We assessed 92 patients. Before coronary angiography, endothelial function was measured by RH-PAT and reactive hyperemia index (RHI) was obtained. For each patient, the Gensini score was calculated according to the coronary angiographic findings to evaluate the severity of CAD.Entities:
Keywords: Coronary artery disease; Endothelial dysfunction; Peripheral arterial tonometry; Reactive hyperemia index
Mesh:
Year: 2022 PMID: 35051935 PMCID: PMC9274820 DOI: 10.1159/000522098
Source DB: PubMed Journal: Med Princ Pract ISSN: 1011-7571 Impact factor: 2.132
Fig. 1Measurement of reactive hyperemia-peripheral arterial tonometry, Endo-PAT 2000 device (a) system and finger alignment (b) are shown. On the right side, an example of an HF patient with ED (c) and normal endothelial function (d) are shown.
Demographic characteristics, associated risk factors, medications, and laboratory findings
| Parameter | Total ( |
|---|---|
| Age, year | 59.7±12.0 |
| Gender, male, | 59 (64.1) |
| BMI, kg/m2 | 29.2±4.4 |
| Waist circumference, cm | 102.4±12.4 |
| Diabetes, | 27 (29.3) |
| Hypertension, | 48 (52.2) |
| Hyperlipidemia, | 28 (30.4) |
| Smokers, | 22 (23.9) |
| Acetylsalicylic acid, | 31 (33.7) |
| Beta blocker, | 19 (20.7) |
| Calcium channel blocker, | 10 (10.8) |
| ACE inhibitor, | 35 (38.0) |
| Statin, | 25 (27.2) |
| LDL, mg/dL | 132.9±34.6 |
| HDL, mg/dL | 50.4±13.8 |
| Triglyceride, mg/dL | 161.0±84.2 |
| Fasting blood glucose, mg/dL | 107.3±37.4 |
| Mean RHI | 1.55±0.42 |
BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RHI, reactive hyperemia index.
Demographic characteristics, risk factors, drugs, and laboratory findings of the groups according to the presence of CAD as detected by coronary angiography
| CAD (+) ( | CAD (−) ( | ||
|---|---|---|---|
| Age, years | 64.4±10.5 | 55.2±11.7 | 0.001 |
| BMI, kg/m2 | 29.0±4.7 | 29.40±4.03 | 0.694 |
| Waist circumference, cm | 104.2±12.8 | 100.6±11.8 | 0.170 |
| Diabetes, | 17 (38.6) | 10 (20.8) | 0.061 |
| Hypertension, | 29 (65.9) | 19 (39.6) | 0.012 |
| Hyperlipidemia, | 15 (34.1) | 13 (27.1) | 0.153 |
| Smokers, | 10 (22.7) | 12 (25.0) | 0.031 |
| Aspirin, | 21 (47.7) | 10 (20.8) | 0.006 |
| Beta blocker, | 11 (25.0) | 8 (16.7) | 0.324 |
| Calcium channel blocker, | 7 (15.9) | 3 (6.3) | 0.137 |
| ACE inhibitor, | 21 (47.7) | 14 (29.2) | 0.067 |
| Statin, | 15 (48.4) | 10 (20.8) | 0.153 |
| LDL, mg/dL | 132.8±28.9 | 133.2±39.6 | 0.959 |
| HDL, mg/dL | 46.9±11.8 | 53.6±14.9 | 0.020 |
| Triglycerides, mg/dL | 176.5±96.6 | 146.9±69.2 | 0.093 |
| Fasting glucose, mg/dL | 116.8±45.3 | 98.8±26.1 | 0.024 |
| Mean RHI | 1.35±0.57 | 1.74±0.46 | 0.001 |
BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CAD, coronary artery disease; RHI, reactive hyperemia index.
Multivariate logistic regression analysis of parameters that were determined to be significantly associated with CAD in univariate logistic regression analysis
| Wald χ2 | Odds ratio | 95% CI | ||
|---|---|---|---|---|
| Year | 8.102 | 0.004 | 1.097 | 1.029–1.169 |
| Smoking | 2.296 | 0.130 | 2.905 | 0.731–11.536 |
| HDL | 4.378 | 0.036 | 0.944 | 0.894–0.996 |
| Creatinine | 0.711 | 0.399 | 0.220 | 0.07–7.424 |
| DBP | 3.022 | 0.082 | 1.060 | 0.993–1.132 |
| RHI | 5.188 | 0.023 | 0.069 | 0.07–0.689 |
DBP, diastolic blood pressure; HDL, high-density lipoprotein, RHI, reactive hyperemia index.
Fig. 2ROC analysis for RHI in predicting CAD risk.
Fig. 3Association of RHI with the Gensini score.